Plamotamab (CD3E/MS4A1) - Research Grade Biosimilar

• Background:

  Plamotamab (XmAb13676) is a tumor-targeted antibody that contains both a CD20 binding domain and a cytotoxic T-cell binding domain (CD3) .An XmAb Bispecific Fc domain serves as the scaffold for these two antigen binding domains and confers long circulating half-life, stability and ease of manufacture on plamotamab.CD20 is highly expressed on B-cell tumor cells, including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) cells.Engagement of CD3 by plamotamab activates T cells for highly potent and targeted killing of CD20-expressing tumor cells. The structural stability and modularity enabled by the XmAb Bispecific Fc domain allowed the tuning of plamotamab’s potency to balance anti-tumor activity with the reduction of immune toxicity that can result from T-cell activation.

• Immunogen:

  Chimeric, Humanized / CD3E/MS4A1 [Homo sapiens]

• Clonality:

  Recombinant Monoclonal

• Conjugation:

  Unconjugated

• Type:

  Primary Antibodies, Biosimilars

• Source:

  CHO cells

• Field of Research:

  Cancer

• Purification:

  >95%

• Concentration:

  Batch dependent

• Buffer:

  PBS buffer pH7.5

• Modification:

  None

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚ C for 1-2 weeks. Store at -20 ˚ C for 12 months. Store at -80 ˚ C for long term storage.

• Fragment:

  IgG1-kappa / scFv-h-CH2-CH3

• NCBI Organism:

  Homo sapiens

• Other Product Names:

  XmAb-13676